The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Impact of Pathological Characteristics on Local Relapse After Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost Trial
Open accessAbstract
Purpose: To investigate the long-term impact of pathologic characteristics and an extra boost dose of 16 Gy on local relapse, for stage I and II invasive breast cancer patients treated with breast conserving therapy (BCT). Patients and Methods: In the European Organisation for Research and Treatment of Cancer boost versus no boost trial, after whole breast irradiation, patients with microscopically complete excision of invasive tumor, were randomly assigned to receive or not an extra boost dose of 16 Gy. For a subset of 1,616 patients central pathology review was performed. Results: The 10-year cumulative risk of local breast cancer relapse as a first event was not significantly influenced if the margin was scored negative, close or positive for invasive tumor or ductal carcinoma in situ according to central pathology review (log-rank P = .45 and P = .57, respectively). In multivariate analysis, high-grade invasive ductal carcinoma was associated with an increased risk of local relapse (P = .026; hazard ratio [HR], 1.67), as was age younger than 50 years (P < .0001; HR, 2.38). The boost dose of 16 Gy significantly reduced the local relapse rate (P = .0006; HR, 0.47). For patients younger than 50 years old and in patients with high grade invasive ductal carcinoma, the boost dose reduced the local relapse from 19.4% to 11.4% (P = .0046; HR, 0.51) and from 18.9% to 8.6% (P = .01; HR, 0.42), respectively. Conclusion: Young age and high-grade invasive ductal cancer were the most important risk factors for local relapse, while margin status had no significant influence. A boost dose of 16 Gy significantly reduced the negative effects of both young age and high-grade invasive cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., Jeong, J.-H., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa022152 · Cited by 6,249
Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., Aguilar, M., & Marubini, E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020989 · Cited by 4,450
van Dongen, J. A. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.14.1143 · Cited by 1,271
Jacobson, J. A., Danforth, D. N., Cowan, K. H., d'Angelo, T., Steinberg, S. M., Pierce, L., Lippman, M. E., Lichter, A. S., Glatstein, E., & Okunieff, P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321402 · Cited by 892 · cited 1×
“noma treated with BCT will have a local relapse within 10 years.(1-10) We and Romestaing et al(11-13)”
BackgroundArriagada, R., Lê, M. G., Rochard, F., & Contesso, G. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1558 · Cited by 612 · cited 1×
“noma treated with BCT will have a local relapse within 10 years.(1-10) We and Romestaing et al(11-13)”
Background
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Bartelink, H., Maingon, P., Poortmans, P., Weltens, C., Fourquet, A., Jager, J., Schinagl, D., Oei, B., Rodenhuis, C., Horiot, J.-C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71156-8 · Cited by 685
Self-citationHoussami, N., Macaskill, P., Luke Marinovich, M., & Morrow, M. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3480-5 · Cited by 532
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.3935 · Cited by 451
Molecular Subtypes and Local-Regional Control of Breast Cancer
Fragomeni, S. M., Sciallis, A., & Jeruss, J. S. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.08.005 · Cited by 450
Metadata
- Authors
- Jones, H. A., Antonini, N., Hart, A. A. M., Peterse, J. L., Horiot, J.-C., Collin, F., Poortmans, P. M., Oei, S. B., Collette, L., Struikmans, H., Van den Bogaert, W. F., Fourquet, A., Jager, J. J., Schinagl, D. A. X., Wárlám-Rodenhuis, C. C., & Bartelink, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-10-20
- Volume
- 27
- Issue
- 30
- Pages
- 4939-4947
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123553402
- Cited by
- 239
- References
- 5
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Pathological Characteristics on Local Relapse After Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost Trial. https://app.cochat.ai/papers/10.1200/jco.2008.21.5764
- The paper
- Jones, H. A., Antonini, N., Hart, A. A. M., Peterse, J. L., Horiot, J.-C., Collin, F., Poortmans, P. M., Oei, S. B., Collette, L., Struikmans, H., Van den Bogaert, W. F., Fourquet, A., Jager, J. J., Schinagl, D. A. X., Wárlám-Rodenhuis, C. C., & Bartelink, H. (2009). Impact of Pathological Characteristics on Local Relapse After Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.21.5764
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.